Interpace Biosciences (Interpace Biosciences) Inventory-to-Revenue : 0.11 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Interpace Biosciences's Average Total Inventories for the quarter that ended in Dec. 2023 was $1.16 Mil. Interpace Biosciences's Revenue for the three months ended in Dec. 2023 was $10.28 Mil. Interpace Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.11.

Interpace Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Sep. 2023 (0.00) to Sep. 2023 (0.11)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Interpace Biosciences's Days Inventory for the three months ended in Dec. 2023 was 25.52.

Inventory Turnover measures how fast the company turns over its inventory within a year. Interpace Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 was 3.58.

Interpace Biosciences Inventory-to-Revenue Historical Data

The historical data trend for Interpace Biosciences's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Inventory-to-Revenue Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.08

0.06

0.04

0.03

Interpace Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															0.15	0.12	0.11	-	0.11

Competitive Comparison of Interpace Biosciences's Inventory-to-Revenue

For the Diagnostics & Research subindustry, Interpace Biosciences's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Interpace Biosciences's Inventory-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Inventory-to-Revenue falls into.

Interpace Biosciences Inventory-to-Revenue Calculation

Interpace Biosciences's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (1.224	+	1.227)	/	2 )	/	40.214
=	1.2255					/	40.214
=	0.03

Interpace Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (1.093	+	1.227)	/	2 )	/	10.283
=	1.16					/	10.283
=	0.11

Interpace Biosciences (OTCPK:IDXG) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Interpace Biosciences's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	1.16	/	4.147	*	365 / 4
	=	25.52

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Interpace Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	4.147	/	1.16
	=	3.58

Interpace Biosciences Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (Interpace Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

PF42:Germany

Address

300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Executives

Christopher Mccarthy	officer: Principal Financial Officer	C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal	director	2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell	director, officer: President and CEO	1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin	10 percent owner	2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel	officer: Chief Financial Officer	REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca	director	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan	director	C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p.	10 percent owner	2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy	director	2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership	10 percent owner	55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev	director, 10 percent owner	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg	officer: Chief Accounting Officer	INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard	officer: Chief Commerical Officer	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054